[
    {
        "pregunta": "1. What are the primary objectives of the 2015 recommendations for the management of Polymyalgia Rheumatica (PMR)?",
        "respuesta": "The primary objectives of the 2015 recommendations for the management of Polymyalgia Rheumatica (PMR) are to guide the management of patients with PMR in various settings. These recommendations are based on clinical evidence and expert opinion, including informed patient decision-making. They are intended to assist clinicians in managing PMR patients effectively, with consideration given to individual patient circumstances.",
        "contexto": [
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate",
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "2015 Recommendations for the Management of Polymyalgia Rheumatica A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative  Abbott  Roche  MSD  Bristol-Myers Squibb  GlaxoSmithKline  Celgene  American College of Rheumatology  Mundipharma  Merck  Amgen  Roche/Genentech  Berlin-Chemie  Mesoblast  Novartis  Centocor/Janssen  Sanofi  AbbVie  Genentech  Pfizer  Medac  European League Against Rheumatism  Servier  Ardea   October 2015     October 2015 4E3758F727ED5D273FE5CEB52C36D18A 10.1002/art.39333 Submitted for publication February 20, 2015; accepted in revised form July 13, 2015.  Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to",
            "diagnoses. \" Determination of comorbidities (particularly hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis [and particularly recent fractures]), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with non-steroidal anti-inflammatory drugs (NSAIDs) as outlined in Smolen et al the specific treatment recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for"
        ]
    },
    {
        "pregunta": "2. Who are the target users of these recommendations?",
        "respuesta": "The target users of the 2015 recommendations for the management of Polymyalgia Rheumatica (PMR) are primary, secondary, and tertiary care physicians, which include general practitioners (GPs), specialists in general (internal) medicine, and rheumatologists.",
        "contexto": [
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate",
            "evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Target users. The target users of these recommendations are primary, secondary and tertiary care physicians (that is, general practitioners [GPs], specialists in general [internal] medicine and rheumatologists). Methods For a detailed description of methods, see online supplementary file S1, on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ In brief, we used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework http://onlinelibrary.wiley.com/ http://onlinelibrary S1 http:// onlinelibrary.wiley.com/doi/10.1002/art.39333/abstract Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by",
            "2015 Recommendations for the Management of Polymyalgia Rheumatica A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative  Abbott  Roche  MSD  Bristol-Myers Squibb  GlaxoSmithKline  Celgene  American College of Rheumatology  Mundipharma  Merck  Amgen  Roche/Genentech  Berlin-Chemie  Mesoblast  Novartis  Centocor/Janssen  Sanofi  AbbVie  Genentech  Pfizer  Medac  European League Against Rheumatism  Servier  Ardea   October 2015     October 2015 4E3758F727ED5D273FE5CEB52C36D18A 10.1002/art.39333 Submitted for publication February 20, 2015; accepted in revised form July 13, 2015.  Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to"
        ]
    },
    {
        "pregunta": "3. What are the overarching principles for the management of PMR as outlined in the guidelines?",
        "respuesta": "The overarching principles for the management of Polymyalgia Rheumatica (PMR) as outlined in the 2015 guidelines include:\n\n1. Adoption of a safe and specific approach to ascertain the PMR case definition. This involves clinical evaluation aimed at excluding conditions that could mimic PMR, such as non-inflammatory, inflammatory (like giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective, and neoplastic conditions.\n\n2. Every case of PMR should undergo specific assessments before the initiation of therapy. These assessments, conducted in primary or secondary care, include documenting a basic laboratory dataset to exclude mimicking conditions and establish a baseline for monitoring therapy. This should include testing for rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein, and/or erythrocyte sedimentation rate.",
        "contexto": [
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate",
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by",
            "2015 Recommendations for the Management of Polymyalgia Rheumatica A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative  Abbott  Roche  MSD  Bristol-Myers Squibb  GlaxoSmithKline  Celgene  American College of Rheumatology  Mundipharma  Merck  Amgen  Roche/Genentech  Berlin-Chemie  Mesoblast  Novartis  Centocor/Janssen  Sanofi  AbbVie  Genentech  Pfizer  Medac  European League Against Rheumatism  Servier  Ardea   October 2015     October 2015 4E3758F727ED5D273FE5CEB52C36D18A 10.1002/art.39333 Submitted for publication February 20, 2015; accepted in revised form July 13, 2015.  Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "<h1>Table 2. Guiding principles for the integrative management of rheumatoid arthritis*</h1>"
        ]
    },
    {
        "pregunta": "4. What are the recommended assessments that should be conducted prior to prescribing therapy for PMR patients?",
        "respuesta": "Prior to prescribing therapy for patients with Polymyalgia Rheumatica (PMR), the following assessments are recommended:\n\n1. **Documentation of a Basic Laboratory Dataset**: This assessment is crucial to exclude conditions that mimic PMR and to establish a baseline for monitoring therapy. The laboratory tests should include:\n   - Rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA).\n   - C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR).\n\n2. **Determination of Comorbidities**: This involves assessing for the presence of other medical conditions, such as:\n   - Hypertension\n   - Diabetes and glucose intolerance\n   - Cardiovascular disease\n   - Dyslipidemia\n   - Peptic ulcer\n   - Osteoporosis (especially recent fractures)\n   - Cataract or risk factors for glaucoma\n   - Chronic or recurrent infections\n   - Co-medication with non-steroidal anti-inflammatory drugs (NSAIDs).",
        "contexto": [
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "diagnoses. \" Determination of comorbidities (particularly hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis [and particularly recent fractures]), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with non-steroidal anti-inflammatory drugs (NSAIDs) as outlined in Smolen et al the specific treatment recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for",
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by",
            "QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR. The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR?"
        ]
    },
    {
        "pregunta": "5. Why does the panel strongly recommend using glucocorticoids (GCs) instead of NSAIDs in patients with PMR?",
        "respuesta": "The panel strongly recommends the use of glucocorticoids (GCs) over non-steroidal anti-inflammatory drugs (NSAIDs) for patients with Polymyalgia Rheumatica (PMR) due to the relative harm associated with long-term NSAID use outweighing the possible small benefits in managing PMR. While GCs are recommended as the primary treatment option, NSAIDs may be used short-term for managing pain related to conditions other than PMR, such as co-existing osteoarthritis. There is no specific recommendation for the use of analgesics.",
        "contexto": [
            "and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for analgesics. Explanation: The group recommends strongly against the use of NSAIDs compared to GCs in the treatment of PMR since the relative harm of long-term NSAID use (as mainly indicated by external evidence) outweighs the possible small benefits in PMR. No specific recommendation can be made for analgesics. On a basis of consensus, the panel recognized that the short-term use of NSAIDs and/or analgesics may be necessary in the setting of pain related to conditions other than PMR. Recommendation 2: (PICO 2) The panel strongly recommends using the minimum effective individualized duration of GC therapy in PMR patients. A more specific recommendation is not possible due to the lack of published evidence on this issue. On a basis of consensus and in accordance with the overarching principles, the group unanimously agreed to choose the",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "diagnoses. \" Determination of comorbidities (particularly hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis [and particularly recent fractures]), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with non-steroidal anti-inflammatory drugs (NSAIDs) as outlined in Smolen et al the specific treatment recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for",
            "The panel did not specify a clinical phenotype where i.m. GCs would be appropriate or adequate therapy; however, the panel agreed that in clinical practice this preparation may be considered in cases where a lower cumulative GC dose is desirable, for example in female patients with difficult to control hypertension, diabetes, osteoporosis and/or glaucoma The reasons why the panel did not endorse a strong recommendation for the use of i.m. methylprednisolone are the following: 1) the efficacy of i.m. methylprednisolone is supported by a single randomized controlled trial and confirmation of these data is still necessary Recommendation 6: (PICO 8) The panel conditionally recommends using a single rather than divided daily doses of oral GCs for the treatment of PMR, except for special situations such as prominent night pain while tapering GCs below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on",
            "adverse events. The group further agreed that MTX may be used with oral or i.m. GC preparations even if the concomitant use of MTX and i.m. methylprednisolone has not been tested formally. The efficacy of MTX was addressed in four randomized controlled trials and one retrospective study testing the use of MTX plus oral GCs (initial prednisone doses ranging from 15 to 25 mg/day) The reasons why the panel did not support a stronger recommendation for the use of MTX in PMR are the following: 1) the total number of patients investigated in randomized trials was small (n5194) The group recognized that no recommendation can be made for the use of other non-biologic (ie, conventional synthetic and conventional targeted) DMARDs in PMR because of the lack of good evidence from PMR studies. Hydroxychloroquine was investigated by a single very low QoE retrospective study reporting no benefit regarding relapse rate Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of"
        ]
    },
    {
        "pregunta": "6. What is the recommended minimum effective individualized duration of GC therapy for PMR patients?",
        "respuesta": "The recommended minimum effective individualized duration of glucocorticoid therapy for patients with Polymyalgia Rheumatica (PMR) is not specifically determined due to the lack of studies in PMR addressing this topic. However, the provided guidelines suggest using a tapering schedule that assumes a minimum of 12 months of treatment. This recommendation is based on the balance of benefit versus harm, considering factors such as risk of relapse, adverse events, comorbidities, and the necessity for prolonged therapy.",
        "contexto": [
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "evidence on this issue. On a basis of consensus and in accordance with the overarching principles, the group unanimously agreed to choose the minimum effective individualized duration and dose of GCs to balance benefit versus harm after assessing risk factors for GC-related adverse events, comorbidities, concomitant medications, relapses and prolonged therapy. Our recommended GC tapering schedule (see Recommendation 4) assumes a minimum of 12 months of treatment. A more specific statement is not possible because of the lack of PMR studies on this particular topic and because of the multiple subgroups and factors that need to be taken into account. Recommendation 3: (PICOs 3-5) The panel conditionally recommends using the minimum effective GC dose within a range of 12.5-25 mg prednisone equivalent daily as the initial treatment of PMR. A higher initial prednisone dose within this range may be considered in patients with a high risk of relapse and low risk of adverse events, whereas in",
            "patients may benefit from continuing remission maintenance therapy for a longer duration Ungraded position statement: The duration of glucocorticoid therapy for GPA/MPA should be guided by the patient's clinical condition, preferences, and values. The optimal duration of glucocorticoid therapy for GPA/MPA is not well established. The immunosuppressive effects of glucocorticoids contributing to disease control should be balanced with the toxicities associated with its use. Overall, patients expressed a desire to minimize the glucocorticoid dose as much as possible but recognized that some patients may require low-dose glucocorticoids long-term to maintain disease quiescence. Screening for toxicities of glucocorticoid use (e.g., bone mineral density testing for osteoporosis) should be conducted. Treatment of disease relapse Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not receiving rituximab for remission maintenance,",
            "and results from small studies Ungraded position statement: The duration of glucocorticoid therapy in EGPA should be guided by the patient's clinical condition, values, and preferences. There is insufficient published evidence to support a specific duration of glucocorticoid treatment, and thus, the length of glucocorticoid therapy should be determined based on each patient's clinical circumstances. Many patients with EGPA require some treatment with glucocorticoids, generally at a low dose, to maintain control of asthma and allergy symptoms. The minimum effective dose should be prescribed to minimize glucocorticoid toxicity. Treatment of disease relapse Recommendation: For patients with EGPA who have experienced relapse with severe disease manifestations after prior successful remission induction with cyclophosphamide, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction. Rituximab is favored based on the general desire to avoid",
            "recommend a total duration of therapy of at least 3-5 years. IN PEOPLE WITH ACTIVE IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF PURE CLASS V: …With proteinuria ≥1 g/g we conditionally recommend treatment with a TRIPLE immunosuppressive regimen consisting of pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend treatment with glucocorticoids and/or immunosuppressant therapy (MPAA, AZA, or CNI). IN PEOPLE WITH NONRESPONSIVE OR REFRACTORY LN: GPS: Medication dose and patient adherence should be assessed as an important first step in evaluating inadequate response or refractory LN, as insufficient treatment is an important cause of non-response. In people with any LN class with an inadequate renal response (i.e., have not achieved at least a partial renal response by 6-12 months) we conditionally recommend"
        ]
    },
    {
        "pregunta": "7. What is the suggested initial prednisone dose range for the treatment of PMR patients?",
        "respuesta": "The suggested initial prednisone dose range for the treatment of Polymyalgia Rheumatica (PMR) patients is 12.5-25 mg prednisone equivalent daily. A higher initial prednisone dose within this range may be considered in patients with a high risk of relapse and low risk of adverse events, whereas a lower dose may be preferred in patients with relevant comorbidities and other risk factors for glucocorticoid-related side effects.",
        "contexto": [
            "higher initial prednisone dose within this range may be considered in patients with a high risk of relapse and low risk of adverse events, whereas in patients with relevant comorbidities (eg, diabetes, osteoporosis, glaucoma, etc.) and other risk factors for GC-related side effects, a lower dose may be preferred. The panel discourages conditionally the use of initial doses #7.5 mg/day and strongly recommends against the use of initial doses .30 mg/day. According to the SLR on prognostic factors and based on clinical experience, the group agreed upon the existence of various PMR subgroups that are characterized by different risks of relapse, prolonged GC therapy and/or GC-related adverse events as well as by various comorbidities and co-medications. As there are insufficient data to make evidence-based recommendations for all conceivable subgroups, and taking current clinical practice into account The group conditionally discourages low (#7.5 mg/ day) and strongly recommends against",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "evidence on this issue. On a basis of consensus and in accordance with the overarching principles, the group unanimously agreed to choose the minimum effective individualized duration and dose of GCs to balance benefit versus harm after assessing risk factors for GC-related adverse events, comorbidities, concomitant medications, relapses and prolonged therapy. Our recommended GC tapering schedule (see Recommendation 4) assumes a minimum of 12 months of treatment. A more specific statement is not possible because of the lack of PMR studies on this particular topic and because of the multiple subgroups and factors that need to be taken into account. Recommendation 3: (PICOs 3-5) The panel conditionally recommends using the minimum effective GC dose within a range of 12.5-25 mg prednisone equivalent daily as the initial treatment of PMR. A higher initial prednisone dose within this range may be considered in patients with a high risk of relapse and low risk of adverse events, whereas in",
            "below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on clinical experience and because of the concern that adverse events (including disturbance of the hypothalamic-pituitary-adrenal axis) may be higher with divided doses, the group agreed against the general use of divided GC doses in PMR In special situations such as in case of night pain while tapering below the low-dose range (prednisone or equivalent ,5 mg daily), split doses may be considered. However, persistent breakthrough symptoms should prompt re-consideration of the diagnosis. Recommendation 7: (PICO 9) The panel conditionally recommends considering early introduction of MTX in addition to GCs, particularly in patients at high risk of relapse and/or prolonged therapy as well as in cases with risk factors, comorbidities and/or concomitant medications where GC-related adverse events are more likely to occur. MTX may also be",
            "The panel did not specify a clinical phenotype where i.m. GCs would be appropriate or adequate therapy; however, the panel agreed that in clinical practice this preparation may be considered in cases where a lower cumulative GC dose is desirable, for example in female patients with difficult to control hypertension, diabetes, osteoporosis and/or glaucoma The reasons why the panel did not endorse a strong recommendation for the use of i.m. methylprednisolone are the following: 1) the efficacy of i.m. methylprednisolone is supported by a single randomized controlled trial and confirmation of these data is still necessary Recommendation 6: (PICO 8) The panel conditionally recommends using a single rather than divided daily doses of oral GCs for the treatment of PMR, except for special situations such as prominent night pain while tapering GCs below the low-dose range (prednisone or equivalent ,5 mg daily). There are no studies available addressing this issue specifically in PMR. Based on"
        ]
    },
    {
        "pregunta": "8. How should the dose-tapering schedules for GC therapy be individualized for PMR patients?",
        "respuesta": "The tapering schedules for glucocorticoid therapy in patients with Polymyalgia Rheumatica (PMR) should be individualized based on several factors. The panel recommends a flexible approach that takes into account the minimum effective dose and duration to balance the benefit versus the risk associated with glucocorticoid use. Key considerations include:\n\n1. **Gradual Reduction**: Once remission is achieved, glucocorticoids can be tapered by 1 mg every 4 weeks or using similar schedules, ensuring careful monitoring of the disease activity. \n\n2. **Risk Factors**: Individual patient factors such as risk of relapse, comorbidities, concomitant medications, and glucocorticoid-related adverse events must be assessed.\n\n3. **Patient Monitoring**: Patients should be regularly monitored during the tapering process, and if a flare occurs, the prior regimen should be promptly reinstituted.\n\n4. **No Fixed Schedule**: While principles for tapering are provided, there is no fixed tapering schedule due to variations in patient response and the unavailability of 1 mg prednisone tablets in some countries.\n\nThese guidelines emphasize individualized treatment, urging regular evaluations to adjust tapering schedules based on each patient's unique situation.",
        "contexto": [
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when and how best to taper. The panel recommended that careful tapering might be considered if the patient wishes to cut back on their use of DMARDs. However, patients should be closely evaluated during any taper, and if a flare occurs, the prior regimen should be reinstituted promptly. Last, this update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2 issues required prolonged discussion and debate. The decision",
            "initial and relapse therapies): Taper daily oral prednisone by 1 mg every 4 weeks (or by 1.25 mg decrements using schedules such as 10/7.5 mg on alternate days, etc.) until discontinuation as long as remission is maintained. In accordance with the overarching principles, the panel agreed upon a strong recommendation to 2574 DEJACO ET AL individualize dose tapering and to regularly monitor PMR patients. Further, the panel proposed general principles for initial and post-relapse tapering of GCs (based on consensus and current clinical practice) but did not fix a schedule as in other guidelines The group suggested prednisone should be tapered by 1 mg/4 weeks or similar once remission is achieved. Again, the panel emphasized the important overall principle of gradual GC reduction without the need to prescribe a fixed schedule. The group further recognized that 1 mg prednisone tablets are not available in all countries (making a reduction of 1 mg/4 weeks unfeasible) and that other regimens",
            "evidence on this issue. On a basis of consensus and in accordance with the overarching principles, the group unanimously agreed to choose the minimum effective individualized duration and dose of GCs to balance benefit versus harm after assessing risk factors for GC-related adverse events, comorbidities, concomitant medications, relapses and prolonged therapy. Our recommended GC tapering schedule (see Recommendation 4) assumes a minimum of 12 months of treatment. A more specific statement is not possible because of the lack of PMR studies on this particular topic and because of the multiple subgroups and factors that need to be taken into account. Recommendation 3: (PICOs 3-5) The panel conditionally recommends using the minimum effective GC dose within a range of 12.5-25 mg prednisone equivalent daily as the initial treatment of PMR. A higher initial prednisone dose within this range may be considered in patients with a high risk of relapse and low risk of adverse events, whereas in",
            "research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR? What is the value of a composite score? What are the most relevant treatment targets in PMR? 2. What is the efficacy and safety of different routes of glucocorticoid (GC) administration (oral, intramuscular, intra-articular), different initial GC doses, various GC tapering regimens, and different GC flare doses? 3. What is the efficacy and safety of DMARDs (non-TNFa biologic, conventional synthetic and conventional targeted) in PMR? What is the optimal strategy for using DMARDs in PMR: monotherapy versus combination therapy, early versus late introduction, and (particularly for biologics) use with or without GCs? 4. What is the minimal/optimal duration of therapy and which strategies for withdrawing GCs and/or DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including"
        ]
    },
    {
        "pregunta": "9. What are the principles for tapering GC doses once remission is achieved in PMR patients?",
        "respuesta": "The principles for tapering glucocorticoid doses once remission is achieved in patients with Polymyalgia Rheumatica (PMR) are as follows:\n\n1. **Gradual Reduction**: Glucocorticoids should be tapered slowly, with a common recommendation being to reduce the dose by 1 mg every 4 weeks or using similar schedules, as long as remission is maintained.\n\n2. **Individualization**: The tapering schedule should be individualized, taking into account the patient's risk of relapse, comorbidities, concomitant medications, and potential adverse events related to glucocorticoid use.\n\n3. **Patient Monitoring**: Regular monitoring during the tapering process is essential to detect any signs of disease flare, which would necessitate promptly reinstituting the prior glucocorticoid regimen.\n\n4. **No Fixed Schedule**: There is no fixed tapering schedule due to variability in patient response and practical issues, such as the unavailability of 1 mg prednisone tablets in some countries. Therefore, individualized regimens should be developed based on each patient's unique circumstances.\n\nThese principles emphasize a flexible and patient-centered approach to tapering glucocorticoids in PMR treatment.",
        "contexto": [
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when and how best to taper. The panel recommended that careful tapering might be considered if the patient wishes to cut back on their use of DMARDs. However, patients should be closely evaluated during any taper, and if a flare occurs, the prior regimen should be reinstituted promptly. Last, this update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2 issues required prolonged discussion and debate. The decision",
            "initial and relapse therapies): Taper daily oral prednisone by 1 mg every 4 weeks (or by 1.25 mg decrements using schedules such as 10/7.5 mg on alternate days, etc.) until discontinuation as long as remission is maintained. In accordance with the overarching principles, the panel agreed upon a strong recommendation to 2574 DEJACO ET AL individualize dose tapering and to regularly monitor PMR patients. Further, the panel proposed general principles for initial and post-relapse tapering of GCs (based on consensus and current clinical practice) but did not fix a schedule as in other guidelines The group suggested prednisone should be tapered by 1 mg/4 weeks or similar once remission is achieved. Again, the panel emphasized the important overall principle of gradual GC reduction without the need to prescribe a fixed schedule. The group further recognized that 1 mg prednisone tablets are not available in all countries (making a reduction of 1 mg/4 weeks unfeasible) and that other regimens",
            "patients may benefit from continuing remission maintenance therapy for a longer duration Ungraded position statement: The duration of glucocorticoid therapy for GPA/MPA should be guided by the patient's clinical condition, preferences, and values. The optimal duration of glucocorticoid therapy for GPA/MPA is not well established. The immunosuppressive effects of glucocorticoids contributing to disease control should be balanced with the toxicities associated with its use. Overall, patients expressed a desire to minimize the glucocorticoid dose as much as possible but recognized that some patients may require low-dose glucocorticoids long-term to maintain disease quiescence. Screening for toxicities of glucocorticoid use (e.g., bone mineral density testing for osteoporosis) should be conducted. Treatment of disease relapse Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not receiving rituximab for remission maintenance,",
            "research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR? What is the value of a composite score? What are the most relevant treatment targets in PMR? 2. What is the efficacy and safety of different routes of glucocorticoid (GC) administration (oral, intramuscular, intra-articular), different initial GC doses, various GC tapering regimens, and different GC flare doses? 3. What is the efficacy and safety of DMARDs (non-TNFa biologic, conventional synthetic and conventional targeted) in PMR? What is the optimal strategy for using DMARDs in PMR: monotherapy versus combination therapy, early versus late introduction, and (particularly for biologics) use with or without GCs? 4. What is the minimal/optimal duration of therapy and which strategies for withdrawing GCs and/or DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including"
        ]
    },
    {
        "pregunta": "10. How should physicians approach the application of the guidelines and recommendations for PMR management in clinical practice?",
        "respuesta": "Physicians should approach the application of the 2015 recommendations and guidelines for the management of Polymyalgia Rheumatica (PMR) in clinical practice by understanding these guidelines as a framework of clinical advice rather than a strict protocol dictating care. The focus is on integrating these recommendations into the clinical setting with consideration for individual patient circumstances. Key points include:\n\n1. **Flexibility and Individualization**: The guidelines emphasize the importance of individualizing treatment plans. This includes considering patient-specific factors like the risk of relapse, comorbidities, and potential adverse events associated with therapy. \n\n2. **Collaborative Decision-Making**: Recommendations stress informed patient decision-making, encouraging collaboration between physician and patient to tailor treatment to individual needs.\n\n3. **Baseline Evaluations**: A thorough evaluation, including a documentation of a basic laboratory dataset and determination of comorbidities, should be conducted to exclude mimicking conditions and guide treatment.\n\n4. **Glucocorticoid Use and Tapering**: The recommendations advocate for glucocorticoids as the primary treatment for PMR, with NSAIDs considered only for short-term use in managing pain from conditions other than PMR. The tapering of glucocorticoids should be gradual and patient-specific.\n\nUltimately, the application of these guidelines involves a balance between evidence-based recommendations and clinical judgment, taking into account the unique nuances of each patient's condition and overall health.",
        "contexto": [
            "for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care): \" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate",
            "Results The results of the SLR are reported in a separate manuscript http://onlinelibrary General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances. Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by",
            "2015 Recommendations for the Management of Polymyalgia Rheumatica A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative  Abbott  Roche  MSD  Bristol-Myers Squibb  GlaxoSmithKline  Celgene  American College of Rheumatology  Mundipharma  Merck  Amgen  Roche/Genentech  Berlin-Chemie  Mesoblast  Novartis  Centocor/Janssen  Sanofi  AbbVie  Genentech  Pfizer  Medac  European League Against Rheumatism  Servier  Ardea   October 2015     October 2015 4E3758F727ED5D273FE5CEB52C36D18A 10.1002/art.39333 Submitted for publication February 20, 2015; accepted in revised form July 13, 2015.  Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to",
            "and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making. Target population. The target population are patients with PMR based on",
            "diagnoses. \" Determination of comorbidities (particularly hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis [and particularly recent fractures]), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with non-steroidal anti-inflammatory drugs (NSAIDs) as outlined in Smolen et al the specific treatment recommendations and are of a general \"overarching\" nature, a concept adapted from earlier EULAR recommendations Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure 1 Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for"
        ]
    }
]